02627.HK
Ab&B Bio Tech Co Ltd.
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 29.32
−1.01%Income statement
| Metric | TTM | 2024 | 2023 |
|---|---|---|---|
| Revenue | |||
| Total Revenue | 78.1M | 259.6M | 52.2M |
| Cost of Revenue | 22.9M | 108.2M | 72.5M |
| Gross Profit | 55.2M | 151.5M | (20.3M) |
| Operating Expenses | |||
| R&D Expense | 198.7M | 205.6M | 283.2M |
| SG&A Expense | 130.1M | 123.0M | 49.4M |
| General & Admin Expense | 58.1M | 8.9M | 19.3M |
| Selling & Marketing Expense | 72.1M | 114.1M | 30.1M |
| Other Expenses | (21.8M) | 52.0M | 69.6M |
| Total Operating Expenses | 307.0M | 380.5M | 402.2M |
| Cost and Expenses | 330.0M | 488.7M | 474.7M |
| Operating Income (EBIT) | (251.9M) | (229.1M) | (422.6M) |
| Non-Operating | |||
| Interest Income | 481.0K | 474.0K | 3.2M |
| Interest Expense | 18.1M | 17.7M | 6.6M |
| Net Interest Income | (17.6M) | (17.2M) | (3.5M) |
| Other Non-Op Income/Expense | (25.5M) | (29.6M) | (2.2M) |
| Non-Operating Income (excl Interest) | 7.4M | 11.9M | (4.4M) |
| EBT (Pre-Tax Income) | (277.3M) | (258.7M) | (424.7M) |
| Income Tax Expense | — | — | — |
| Bottom Line | |||
| Net Income | (277.3M) | (258.7M) | (424.7M) |
| Earnings from Cont. Ops | (277.3M) | (258.7M) | (424.7M) |
| Earnings from Discont. Ops | — | — | — |
| Bottom Line Net Income | (277.3M) | (258.7M) | (424.7M) |
| Per Share | |||
| Basic EPS | (HK$0.71) | (HK$0.66) | (HK$1.08) |
| Diluted EPS | (HK$0.71) | (HK$0.66) | (HK$1.08) |
| Revenue Per Share | HK$0.20 | HK$0.66 | HK$0.13 |
| Shares | |||
| Basic Shares Outstanding | 393.4M | 393.4M | 393.4M |
| Diluted Shares Outstanding | 393.4M | 393.4M | 393.4M |
| Profitability Metrics | |||
| EBITDA | (228.8M) | (181.8M) | (370.2M) |
| D&A | 30.5M | 59.2M | 48.0M |
| EBIT | (259.2M) | (241.0M) | (418.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2025